Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor

NCT07766421 is registered in ClinicalTrials.gov with Cellectar Biosciences, Inc. as lead sponsor.

NCT NCT07766421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07766421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor
Lead sponsor
Cellectar Biosciences, Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
January 31, 2035
Enrollment
219 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom macroglobulinaemia, waldenstrom macroglobulinemia, waldenstrom macroglobulinemia with nodal disease, waldenstrom's macroglobulinaemia refractory, waldenstrom's macroglobulinemia recurrent